Skip to main content

Chinese internet hospital nets $20M in US listing and more briefs

Also, health IT company UCrest from Malaysia has received its first patent for its AI-powered digital platform from Taiwan.
By Adam Ang
Zhenyang Shi, chairman and CEO of PomDoctor, rings the opening bell following their company's Nasdaq debut

Photo courtesy of Nasdaq

Chinese internet hospital makes $20M Nasdaq debut

PomDoctor, an online medical services provider in China, has raised $20 million in its initial public offering.

The company, now trading on the Nasdaq Global Market, operates one of China's largest digital platforms for chronic disease management and pharmaceutical services, connecting over 200,000 doctors and nearly 700,000 patients. It began as a mobile health service provider in 2015.


UCrest obtains AI patent in Taiwan

Malaysian health IT company UCrest has secured its first patent from Taiwan for its AI-powered digital platform for health management and telemedicine.

Based on a press release, the patent covers the platform's AI-powered diagnostics, personalised health analytics, and remote patient management capabilities. iMedic is powered by AI, blockchain, the Internet of Things, and data analytics integrated with an EMR system. 

Over the past three years, UCrest has filed seven patents for its platform globally, including in the United States, Europe, China, and under the Patent Cooperation Treaty.


Owlet secures first India regulatory nod 

New York-listed Owlet has received approval from India’s Central Drugs Standard Control Organization (CDSCO) to distribute its wearable smart baby monitor.

It is the first among its suite of infant monitoring solutions that has been approved for distribution in the country. It also offers a video camera, a combined sock and video camera monitoring system, and a mobile app for tracking live health readings.

The company targets a full launch of its baby monitoring system in India next year, 2026. 


Neurophet establishes US subsidiary

Stroke AI company Neurophet from South Korea has announced the establishment of a subsidiary in Delaware to hasten its expansion into the US market.

The new entity, expected to be fully incorporated this month, will enable Neurophet to supply its AI-powered brain imaging and diagnostic solutions directly to American healthcare settings. The company has received two US Food and Drug Administration 510(k) clearances for its software, Neurophet AQUA.